Fairvalue-Calculator Fairvalue-Calculator
EN DE

UCB SA (UCBJF) Fair Value & Analysis

Healthcare · US · Market cap $55.4B

Price$290.81
Fair Value$157.97
Upside-45.7%
Quality95/100
Evidence: High Range $118.48 – $197.46

Fair value as of: Jun 24, 2026

Analysis

UCB SA (UCBJF) currently trades at $290.81, while our model-based Fair Value estimate is $157.97 — implying the stock looks roughly 45.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops K…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82% CSL Limited (CSLLY) +36%

Frequently asked questions

Is UCB SA (UCBJF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $157.97 versus a price of $290.81 — about −46% (overvalued). Model-based estimate, not financial advice.
What is the fair value of UCBJF?
Our 21-model fair value for UCB SA is $157.97 (as of Jun 24, 2026), built from audited fundamentals. The current price is $290.81.
What is the quality score of UCBJF?
UCB SA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.